The temporary ban on the Japanese arm of Novartis from manufacturing or selling prescription products begins today. It is alleged the company manipulated clinical trial data and failed to declare side effects in a timely fashion. The suspension will last 15 days. According to Reuters an internal probe revealed 3,200 side effect cases linked to 26 types of drugs went unreported.